Alzheimer's disease (AD) is a devastating neurodegenerative disorder that is growing in prevalence globally. It is the only major cause of death without any effective pharmacological means to treat or slow progression. Inheritance of the ε4 allele of the Apolipoprotein (APO) E gene is the strongest genetic risk factor for late-onset AD. The interaction between APOE and amyloid β (Aβ) plays a key role in AD pathogenesis. The APOE-Aβ interaction regulates Aβ aggregation and clearance and therefore directly influences the development of amyloid plaques, congophilic amyloid angiopathy and subsequent tau related pathology. Relatively few AD therapeutic approaches have directly targeted the APOE-Aβ interaction thus far. Here we review the critical role of APOE in the pathogenesis of AD and some of the most promising therapeutic approaches that focus on the APOE-Aβ interaction.
pharmaceutical agents exist to halt or slow disease progression. AD is defined neuropathologically by the accumulation of amyloid β (Aβ) into extracellular plaques in the brain parenchyma and in the vasculature (known as congophilic [or cerebral] amyloid angiopathy [CAA]), and abnormally phosphorylated tau that accumulates intraneuronally to form neurofibrillary tangles (NFTs) (2) (3) (4) . In our early studies, we discovered that apolipoprotein E (APOE) was a new amyloid-associated protein that was abundantly present in amyloid plaques. We hypothesized that APOE was a "pathological chaperone" that directly promoted aggregation/fibrillization of Aβ (5, 6) . Subsequent work by Dr. Allen Roses and his group identified the ε4 allele of the APOE gene as a key genetic risk factor for AD (7) (8) (9) . This seminal observation was confirmed in other populations in the US, Europe and Australia (10) (11) (12) . Many confirmatory studies have now shown that the APOE4 genotype is the most common and potent AD genetic risk factor identified thus far (13) (14) (15) (16) (17) . Our work and that of others showed that APOE4 particularly promoted Aβ oligomerization/fibrillization in comparison to APOE2 or APOE3 (6, (18) (19) (20) (21) (22) (23) (24) (25) (26) . This effect was associated with an earlier onset of disease and greater amyloid plaque and CAA burden, in both patients and AD model transgenic mice expressing different human APOE genotypes (APOE4 > APOE3 > APOE2) (14, (27) (28) (29) (30) (31) (32) (33) (34) .
Phosphorylated tau and Aβ pathologically aggregate in a sequential process. Monomers first aggregate into oligomers intraneuronally, which then further aggregate into the fibrils observed in amyloid plaques and NFTs. This pathology then spreads throughout the brain in a characteristic manner that is distinct for NFTs and plaques (35) (36) (37) (38) . This process develops over two to three decades resulting in a long preclinical period when AD associated neuropathology is present in the brain without any associated cognitive impairment (14, 15, 39, 40) . Significant evidence indicates that oligomers of Aβ and tau are the most neurotoxic species in AD as levels of oligomers correlate better with cognitive decline compared to the burden of plaques or NFTs (36, (41) (42) (43) . APOE genotype determines the age of onset for Alzheimer's disease (APOE4<APOE3<APOE2) and directly influences the pathological aggregation of Aβ. Specifically, the Aβ-APOE interaction plays a key role in stabilizing toxic oligomers of Aβ, with APOE4 having a particularly pathological influence (44) (45) (46) .
In familial early onset AD (EOAD) there is either increased production of soluble Aβ (sAβ) or the production of more aggregation prone species, while in sporadic late onset AD (LOAD) there is impaired clearance of soluble Aβ (36) . EOAD pathology is also universal in Down syndrome (DS), which is attributed to the increased production of Aβ in DS due to the presence of three copies of the amyloid precursor protein (47, 48) . Autosomal dominant mutations in presenilin 1, presenilin 2 (PSEN1 and PSEN2) or the amyloid precursor protein (APP) account for only~10% of all EOAD cases (~1% of all AD cases), leaving the cause of the majority of EOAD unexplained (49) (50) (51) (52) . LOAD afflicts >95% of patients with AD and is related to both genetic and environmental factors (50, (53) (54) (55) (56) . A combination of genome-wide association studies (GWAS), linkage, and whole genome/exome sequencing have identified over 30 loci that confer increased risk for LOAD, including genes involved in innate immunity, cholesterol metabolism and synaptic/neuronal membrane function, suggesting that the pathogenesis of LOAD has considerable heterogeneity (50, 52, (56) (57) (58) (59) (60) . Of these, APOE is the strongest identified genetic risk factor for LOAD (13, 15, 61, 62) . Variants of another gene that encodes the triggering receptor expressed on myeloid cells 2 (TREM2) have also been reported as a significant risk factor for LOAD, with an odds ratio approaching that of APOE4; however, these TREM2 variants are uncommon (63) (64) (65) .
This genetic diversity that drives AD pathogenesis suggests that AD is a syndrome associated with a neuropathological signature of Aβ and tau oligomer/fibril accumulation, where neither amyloid plaques or NFTs necessarily have a causative role. Our understanding of these complex pathways has greatly increased in recent years; however, despite this expanding knowledge base there has been a very high failure rate of ~99.6% of AD targeting clinical trials (66) (67) (68) . There are many reasons for this high failure rate, which have been reviewed elsewhere (2, 4, 69, 70) ; however, one factor associated with this lack of success is that relatively few therapeutic studies are targeting the critical role of APOE in AD. Even in EOAD and DS, where AD pathology is primarily driven by overproduction of Aβ, expression of the APOE4 genotype has an additive detrimental effect and lowers the age of onset, while APOE2 has a protective effect (71-77). The paramount role APOE in AD pathogenesis is particularly highlighted in a recent report of a patient with the Colombia kindred PSEN1 E280A mutation, which typically causes the clinical onset of mild cognitive impairment (MCI) and dementia at the median ages of 44 and 49 years respectively (78, 79) . This study found that the additional homozygous expression of the rare Christchurch APOE3 mutation of R154S (APOE3ch) resulted in resistance to the effects of the PS1 mutation; the patient did not develop MCI until her seventies, with very little tau pathology being detected by PET tracers (78) . The APOE3ch variant protein has a significantly reduced ability to promote Aβ 1-42 peptide aggregation compared to wild-type APOE3, which was comparable to the effect of APOE2. The R154S mutation is in the region of APOE involved in lipoprotein receptor and heparin sulfate proteoglycan binding (45) . In addition, this region is involved in APOE binding to Aβ. Aβ binds to APOE both at the lipid binding region of residues 244-272 and at the N-terminal domain (80) (81) (82) . This case illustrates the dramatic effect that altering the APOE-Aβ interaction can have in vivo, indicating that abrogation of this interaction is highly protective against the subsequent development of dementia, even in settings with abundant Aβ deposition. Interestingly, another rare APOE variant p.V236E in the lipid-binding, C-terminal domain of APOE (also involved in Aβ binding) is associated with a markedly reduced risk of AD (83) . The key role of APOE in AD pathogenesis may also explain why AD is a uniquely human disease (84, 85) . The most biologically proximate animals to humans are non-human primates (NHP). It is well established that many NHP species develop abundant age dependent amyloid plaques and/or vascular amyloid deposition, yet none of these species develop significant (or any) NFT pathology or AD like dementia (85) (86) (87) . All NHP are homozygous for APOE4, in that NHP APOE has an arginine at positions 112 and 158 (85, 88) . However, NHP APOE has a threonine instead of an arginine at amino acid position 61, causing it to function biologically in a manner similar to APOE3 (85, 88) . Hence, NHP lack a biological APOE4 like protein to interact with Aβ and drive the subsequent steps needed for the emergence of the AD phenotype. These data suggests that the APOE-Aβ interaction could be a highly effective therapeutic target.
2) Targeting the Major Genetic Risk Factor for AD: Apolipoprotein E4
APOE has pleiotropic functions in the CNS that include being the major CNS cholesterol and other lipid carrier. In addition, it is involved in vascular integrity, synaptic plasticity, glucose metabolism and mitochondrial function (15, 61, 62) . Hence, one important consideration when targeting the role of APOE in AD, is that these normal functions should not be compromised. In addition, APOE is highly expressed outside of the brain, therefore off target effects must be considered when developing a therapeutic approach. Furthermore, APOE concurrently influences both the clearance and aggregation of Aβ in an isotype specific manner (13, 15, 62, (89) (90) (91) (92) ; hence, therapeutic approaches need to carefully balance these potentially opposing roles. In AD, it is still unclear whether the pathogenic role of APOE4 results from a toxic gain of function or loss of protective function. Transgenic mouse studies suggest that APOE4 has a toxic gain of function specifically with regards to its interaction with Aβ, while other pathological effects of APOE4 (e.g. astrocyte activation and synaptic loss) may result from loss of protective function (93) .
APOE enhances aggregation of Aβ in the order of APOE4>APOE3 >APOE2 (5, 21, 23, 26, 94) . APOE isotype specific effects have also been observed with regards to the stabilization of Aβ oligomers, where APOE4 was again shown to have the greatest influence (45, 95) . In physiological conditions, there is relatively minor interaction between APOE and soluble Aβ (96) . Instead, APOJ is the major CNS Aβ binding protein (97, 98) . However, a greater interaction between APOE and Aβ is observed in AD as the aggregate state of Aβ shifts (20, 92, 99) . The finding that APOE4 was less effective in clearing Aβ than APOE3 (100) led to the initial hypothesis that blocking the interaction between Aβ and APOE could decrease the clearance of Aβ and therefore increase the formation of Aβ plaques. However, pivotal in vivo studies show that this does not occur. Blocking the Aβ/APOE interaction instead results in enhanced Aβ clearance from the brain and decreased plaque deposition (101) (102) (103) (104) (105) . This is consistent with the finding that eliminating APOE greatly reduces the amount of amyloid plaque and vessel pathology in AD mouse models (106, 107) . Also supporting the hypothesis that APOE is an AD pathology promoter, rather than APOE4 having a loss of normal Aβ brain clearance function, is human data from a rare individual who lacks APOE due to an ablative APOE frameshift mutation. Despite complete absence of APOE this individual had no cognitive deficits, had normal brain MRI findings and normal CSF levels of Aβ and tau proteins (108) . Multiple approaches for therapeutically targeting APOE in AD have been explored. Major examples of these are listed below.
2.1) Blocking the APOE/Aβ interaction
We have shown that treatment with a peptide that interferes with the Aβ/APOE interaction significantly decreased the amount of both parenchymal and vascular Aβ in three AD transgenic mouse models (101) (102) (103) (104) . This peptide (Aβ12-28P) is homologous to the APOE binding domain of Aβ, and therefore inhibits the Aβ-APOE interaction (109) . The peptide was synthesized with D-amino acids and a proline substitution of valine at residue 18 of Aβ, which improved its resistance to proteolysis and ensures that it is non-toxic and non-fibrillogenic (101, 102) . Treatment of 3xTg mice with this peptide reduced both Aβ and tau pathology, while in TgSwDI mice with extensive CAA, it reduced vascular amyloid pathology (103, 104) . Hence, as illustrated in Figure 1 , altering the APOE-Aβ interaction can reduce all major AD related pathological lesions, in the absence of toxicity such as increased inflammation or microhemorrhages.
Corroborating results from another group have found that Aβ12-28P treatment caused a similar reduction of Aβ oligomer and plaque deposition in amyloid Tg mice with both an APOE2-targeted replacement (TR) or APOE4-TR mouse background, showing that the inhibition of the Aβ/APOE interaction is therapeutically beneficial regardless of the APOE isoform (105) . More recently, we have enhanced our approach for potential future clinical application. We have designed and screened a large group of linear and cyclic peptoid compounds that block the Aβ/APOE interaction in a similar manner, to try to identify a compound that has higher efficacy and safety (110) . The most promising candidate, CPO_Aβ17-21P, inhibited the APOE4/Aβ42 binding at a 2:1 molar ratio and virtually blocked all binding at a 8:1 molar ratio (peptoid:APOE4). This new candidate also had a significantly improved half-maximal inhibition (IC 50 ) in comparison to Aβ12-28P (102) . The Aβ residues between 17-21 appear to be the critical region for Aβ binding to APOE, with the lysine at residue 16 being particularly important (80, 81) , therefore it is consistent that a peptoid conforming to this sequence is an effective inhibitor of the Aβ/APOE interaction. Treatment of APP/PS1 Tg mice with CPO_Aβ17-21P resulted in significant reduction of soluble and insoluble Aβ peptide/oligomer levels in brain, lower numbers of amyloid plaques and significantly improved cognitive function (110) . Importantly, all of these effects were observed after treatment with a 7.5 fold lower dose than required for the Aβ12-28P studies (104, 110) , indicating that CPO_Aβ17-21P has improved bioavailability/biostability over Aβ12-28P. Importantly, treatment of APP/PS1 AD transgenic mice with CPO_Aβ17-21P did not increase the soluble Aβ pool. Additionally, there was no evidence of increased brain inflammation after treatment (110) , which has been another possible concern with therapeutic strategies that target Aβ. We are in the process of using an innovative "scaffold hopping" medicinal chemistry approach (111) from CPO_Aβ17-21P to druglike small molecule candidates, along with a receptor-based scaffold-independent approach to further refine this therapeutic approach. Our preclinical studies in multiple AD models have demonstrated that blocking the APOE/Aβ interaction is a promising therapeutic approach that is capable of reducing AD associated neuropathology and improving cognitive performance, in the absence of toxicity.
2.2) APOE immunotherapy
Immunotherapy using anti-APOE antibodies is also a potential therapeutic strategy for AD. Initial studies showed that treatment with an antibody against endogenous mouse APOE (HJ6.3) significantly reduced Aβ pathology in an AD transgenic mouse model (112, 113) . Recently, this work has been extended to show that treatment with an antibody against human APOE (HAE-4) also significantly reduces Aβ plaque pathology in an AD transgenic mouse model expressing human APOE4 (APPPS1-21/APOE4 mice). This antibody recognizes both APOE3 and APOE4 and preferentially binds to non-lipidated, aggregated APOE (114) . While the exact mechanism of action is still unclear, it was proposed that the binding of anti-APOE antibodies to APOE present in amyloid plaques stimulated microglial activation via their Fc domain, which therefore resulted in plaque clearance. Further testing of this approach is underway; however, one potential problem is that off-target antibody binding may detrimentally interfere with the physiological functions of APOE.
2.3) Altering APOE4 conformation
Another means of ameliorating the pathological interaction between APOE4 and Aβ is to make it behave more like APOE3. The point mutations present in APOE4 result in a unique conformation due to a specific interaction between its amino-terminal and carboxyl terminal domains. Small molecule inhibitors have been developed to interfere with this interaction and therefore alter the conformation of APOE4 so that it resembles that of APOE3 or APOE2 (115) (116) (117) . One of these structure correctors has been shown to reduce the APOE4 effects on Aβ, tau phosphorylation and neurodegeneration in human iPSC derived neurons expressing APOE4 (118) . This approach is being further developed and tested as it is still unclear whether it has therapeutic benefits in vivo.
2.4) Expression of APOE2

J o u r n a l P r e -p r o o f
Another elegant method of targeting the AD pathology promoting effects of APOE4 expression is to genetically drive production of "protective" APOE2 expression. Early studies showed that viral vector mediated expression of APOE2 in AD transgenic mouse models expressing endogenous mouse APOE resulted in significantly reduced amyloid plaque burden, significantly reduced levels of insoluble Aβ42 and Aβ40, and significantly reduced synapse loss around plaques in comparison to viral vector mediated expression of APOE4 (119, 120) . Importantly, it was then shown that viral vector mediated expression of APOE2 partially countered the detrimental effects of human APOE4 expression in AD transgenic mouse models if given at early stages of pathology development: AAV-APOE2 treatment of APP.PS1/APOE-TR mice resulted in significantly decreased levels of insoluble Aβ42 and Aβ40 in the brain (121) .
A more recent study tested the delivery of AAVrh.10hAPOE2-HA, an AAVrh.10 serotype coding for an HA-tagged human APOE2 by intraparenchymal, intracisternal, and intraventricular routes of delivery to the CNS of African Green monkeys (122) . The data showed that while all three routes are capable of mediating APOE2 expression in AD relevant regions, intracisternal delivery of AAVrh.10hAPOE2-HA safely mediated wide distribution of APOE2 with the least invasive surgery, thus potentially providing the optimal strategy to deliver vector-mediated human APOE2 to the CNS. A phase I clinical trial is now on-going in AD APOE4 homozygous patients of AAVrh-10APOE2 delivered by intracisternal injection (123).
2.5) Gene editing APOE4 to APOE3
Direct conversion of APOE4 to APOE2 or APOE3 using a gene editing strategy such as CRISPR could be a potentially straightforward therapeutic approach. Proof-ofconcept studies in vitro using iPSCs and organoids has shown that this approach has potential; conversion of APOE4 to APOE3 in these models was shown to decrease Aβ, and to reduce tau phosphorylation and neurodegeneration (118, 124) . However, using gene editing as a therapeutic approach is still in its infancy and it is not yet known whether this would work in vivo.
3) Summary:
There is extensive evidence that APOE alleles differentially modulate AD pathogenesis by varying effects on net Aβ oligomerization/aggregation versus clearance. The APOE4 isoform remains the most important genetic risk factor for AD. Recent studies have shown strikingly dramatic APOE mediated effects even in the setting of an EOAD PS1 mutation (78, 79) . The road to the discovery of effective AD therapies has been marked by a long string of failures, at least in part, due to relatively J o u r n a l P r e -p r o o f few investigators directly targeting the critical role of APOE in AD. In this review, we summarize a few of what we feel are the most promising on-going approaches to overcome this shortcoming in the field. These approaches have great potential for both the prevention and/or treatment of AD in the absence of significant toxicity. Figure 1 
